ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CVKD vs SXTP // EV/EBITDA & P/E VALUATION

Cadrenal Therapeutics Inc. (NASDAQ) VS. 60 Degrees Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: CVKD 1 — SXTP 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CVKD VS. SXTP) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CVKD SXTP SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 22.30% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 65.50% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 5/9 -3.00 SXTP /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 45.6 48.6 -3.00 SXTP /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $3.4M $3.3M $33.3K CVKD /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CVKD REV SXTP REV CVKD GROSS % SXTP GROSS % CVKD FCF SXTP FCF
FY 2025 $0 $1.0M — 22.3% -$12.6M -$7.0M
FY 2024 $0 $607.6K — 36.7% -$7.4M -$5.8M
FY 2023 $0 $253.6K — — -$3.5M -$4.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CVKD // BETA —
SXTP // BETA —